Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel epilepsy treatments in clinical development.

Epilepsy & behavior : E&B·2026
Same author

CNS Prophylaxis With Intrathecal Cytarabine Post Allogeneic Stem Cell Transplantation in Adult Patients With Acute Lymphoblastic Leukemia: A Monocentric Experience.

Clinical lymphoma, myeloma & leukemia·2026
Same author

The diagnostic value of semiology, EEG and MRI in new-onset pediatric bilateral tonic-clonic seizures: A multimodal analysis.

Epilepsia open·2025
Same author

Long-term seizure and functional outcomes following peri-insular hemispherotomy.

Epilepsy & behavior : E&B·2025
Same author

Prospective evaluation of clinical characteristics, treatment efficacy, and seizure remission in adult-onset genetic generalized epilepsy.

Epilepsia open·2025
Same author

Increased volumes of the precuneus and the pallidum in idiopathic generalized epilepsy.

Scientific reports·2025

Related Experiment Video

Updated: Jun 13, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Emerging drugs for partial onset seizures.

Wassim Nasreddine1, Ahmad Beydoun, Samir Atweh

  • 1Rafik Hariri University Hospital, Department of Neurology, Bir Hasan, Beirut, Lebanon.

Expert Opinion on Emerging Drugs
|May 19, 2010
PubMed
Summary

Emerging antiepileptic drugs (AEDs) show improved pharmacokinetics and tolerability, offering new mechanisms of action. These novel AEDs are expected to have a modest impact on managing drug-resistant epilepsy.

More Related Videos

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

Related Experiment Videos

Last Updated: Jun 13, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Epilepsy affects approximately 1% of the population, leading to recurrent seizures and impacting quality of life.
  • Despite numerous antiepileptic drugs (AEDs), a significant portion of patients experience poorly controlled epilepsy.
  • Social stigma is a considerable challenge for individuals with epilepsy.

Purpose of the Study:

  • To review available antiepileptic drugs (AEDs).
  • To present current information on emerging AEDs, including their pharmacology, mechanism of action, efficacy, and safety.
  • To help readers assess the advantages and potential roles of new AEDs in epilepsy treatment.

Main Methods:

  • Literature review focusing on emerging AEDs published within the last five years.
  • Summarizing data on available AEDs.
  • Detailing chemical structure, pharmacology, mechanism of action, clinical trial efficacy, and adverse event profiles of emerging AEDs.

Main Results:

  • Emerging AEDs generally exhibit enhanced pharmacokinetic properties and better tolerability.
  • Some novel AEDs introduce new mechanisms of action.
  • Clinical trial data on emerging AEDs are presented, allowing for assessment of their therapeutic potential.

Conclusions:

  • Emerging antiepileptic drugs offer improved tolerability and pharmacokinetics.
  • These new AEDs may provide novel mechanisms of action for epilepsy treatment.
  • A modest impact on drug-resistant epilepsy is anticipated from these emerging AEDs.